EG-501 not checked
Evergreen Therapeutics, Inc. · EG-MNTP-01
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “EG-501/ EG-MNTP-01 is an oral, low-affinity NMDA receptor antagonist.”In the company’s words, NCT07281105 on ClinicalTrials.gov
- Tested for
- Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
- Main trialPhase 2
- “Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain fog"), leading to substantial disability, approximately 2 times higher unemployment risk, reduced health-related quality of life (HRQoL), and mortality 2-14 times higher than the general population (standardized mortality ratio, SMR). No approved therapies exist for NPSLE cognitive dysfunction, representing a high-priority unmet need for this FDA-recognized serious…”In the company’s words, NCT07281105 on ClinicalTrials.gov
- Other names
- EG-MNTP-01
Other drugs for Systemic Lupus Erythematosus (SLE)
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 12 Aug 2025 | EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026